

CellProtect

Nordic Pharmaceuticals AB



*Developing innovative cell therapy
treatments for incurable diseases*

Karin Mellström, CEO

5 / 50

Multiple Myeloma is an Incurable and Progressive Hematologic Cancer

First line treatment high dose chemotherapy followed by autologous stem cell transplant (only younger and fit patients)

- prolong remission but does not cure
- *Residual disease is the problem*

How can we complement the existing treatment, eradicate the remaining tumor cells and achieve a cure?


CellProtect

Novel treatment, derived from the patients own immune system - a potential cure for multiple myeloma

CellProtect : autologous *ex vivo* expanded and activated Natural Killer (NK) cells

- NK cells can recognize and kill cancer cells
- In several types of cancer, including multiple myeloma, the tumor cells can evolve to evade and suppress the NK cells killing activity
- The anti-cancer effect of NK-cells is restored by our patented process

Phase I/II, first-in-man, therapeutic exploratory clinical study is on-going



Bone marrow transplant kills majority of MM cells and lowers tumor burden.
CellProtect continues eradication of residual MM cells



Path forward

- continuous evaluation of the phase I/II clinical study
- Establish the regulatory strategy
- Scale up manufacturing procedure with service providers

- Pivotal Phase II (app 200 patients)
- Registration and partnering

Innovationer i
företag
Vinnova

SC1-PM-08–2017:
New therapies for
rare diseases

Market CellProtect after phase II via conditional approval as an Orphan Drug